Remus Pharmaceuticals Past Earnings Performance
Past criteria checks 5/6
Remus Pharmaceuticals has been growing earnings at an average annual rate of 51%, while the Healthcare industry saw earnings growing at 22.9% annually. Revenues have been growing at an average rate of 253.9% per year. Remus Pharmaceuticals's return on equity is 31.8%, and it has net margins of 6.5%.
Key information
51.0%
Earnings growth rate
47.1%
EPS growth rate
| Healthcare Industry Growth | 29.4% |
| Revenue growth rate | 253.9% |
| Return on equity | 31.8% |
| Net Margin | 6.5% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
We Ran A Stock Scan For Earnings Growth And Remus Pharmaceuticals (NSE:REMUS) Passed With Ease
Sep 25
Remus Pharmaceuticals Limited's (NSE:REMUS) P/E Is Still On The Mark Following 28% Share Price Bounce
Aug 20Returns On Capital Signal Tricky Times Ahead For Remus Pharmaceuticals (NSE:REMUS)
Jun 27Concerns Surrounding Remus Pharmaceuticals' (NSE:REMUS) Performance
May 23Remus Pharmaceuticals Limited (NSE:REMUS) Looks Just Right With A 29% Price Jump
May 21Revenue & Expenses Breakdown
How Remus Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 4,565 | 299 | 100 | 0 |
| 30 Jun 24 | 3,347 | 257 | 87 | 0 |
| 31 Mar 24 | 2,129 | 215 | 74 | 0 |
| 31 Mar 23 | 451 | 85 | 55 | 0 |
| 31 Mar 22 | 247 | 34 | 34 | 0 |
| 31 Mar 21 | 188 | 10 | 30 | 0 |
| 31 Mar 20 | 124 | 8 | 31 | 0 |
Quality Earnings: REMUS has high quality earnings.
Growing Profit Margin: REMUS's current net profit margins (6.5%) are lower than last year (11.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: REMUS's earnings have grown significantly by 51% per year over the past 5 years.
Accelerating Growth: REMUS's earnings growth over the past year (99.1%) exceeds its 5-year average (51% per year).
Earnings vs Industry: REMUS earnings growth over the past year (99.1%) exceeded the Healthcare industry 31.4%.
Return on Equity
High ROE: REMUS's Return on Equity (31.8%) is considered high.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/08 20:01 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Remus Pharmaceuticals Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|